Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®

NCT03287128 · clinicaltrials.gov ↗

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Gemtuzumab Ozogamicin (GO)

Sponsor

Versailles Hospital